Rhenman & Partners Asset Management AB as of June 30, 2016
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 97 positions in its portfolio as reported in the June 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals | 4.6 | $26M | 223k | 116.76 | |
| Gilead Sciences (GILD) | 3.6 | $20M | 240k | 83.42 | |
| Celgene Corporation | 3.5 | $20M | 199k | 98.63 | |
| Biogen Idec (BIIB) | 3.4 | $19M | 80k | 241.82 | |
| Eli Lilly & Co. (LLY) | 3.3 | $19M | 235k | 78.75 | |
| Regeneron Pharmaceuticals (REGN) | 3.1 | $17M | 50k | 349.23 | |
| Incyte Corporation (INCY) | 2.4 | $14M | 170k | 79.98 | |
| Pfizer (PFE) | 2.3 | $13M | 375k | 35.21 | |
| CIGNA Corporation | 2.2 | $13M | 99k | 127.99 | |
| UnitedHealth (UNH) | 2.1 | $12M | 85k | 141.20 | |
| Allergan | 2.1 | $12M | 52k | 231.10 | |
| BioMarin Pharmaceutical (BMRN) | 2.1 | $12M | 150k | 77.80 | |
| CVS Caremark Corporation (CVS) | 2.0 | $12M | 120k | 95.74 | |
| Abiomed | 2.0 | $12M | 105k | 109.29 | |
| Medtronic (MDT) | 2.0 | $11M | 127k | 86.77 | |
| Alnylam Pharmaceuticals (ALNY) | 1.9 | $11M | 195k | 55.49 | |
| Bristol Myers Squibb (BMY) | 1.8 | $10M | 137k | 73.55 | |
| Jazz Pharmaceuticals (JAZZ) | 1.8 | $9.9M | 70k | 141.31 | |
| Endo International (ENDPQ) | 1.8 | $9.9M | 635k | 15.59 | |
| Amgen (AMGN) | 1.7 | $9.4M | 62k | 152.15 | |
| Express Scripts Holding | 1.6 | $8.8M | 116k | 75.80 | |
| Zimmer Holdings (ZBH) | 1.5 | $8.5M | 71k | 120.38 | |
| Aetna | 1.4 | $8.2M | 67k | 122.13 | |
| Centene Corporation (CNC) | 1.4 | $8.0M | 112k | 71.37 | |
| Cepheid | 1.4 | $8.0M | 260k | 30.75 | |
| Hca Holdings (HCA) | 1.4 | $7.7M | 100k | 77.01 | |
| Edwards Lifesciences (EW) | 1.2 | $7.0M | 70k | 99.73 | |
| Nektar Therapeutics (NKTR) | 1.2 | $6.7M | 470k | 14.23 | |
| Cardinal Health (CAH) | 1.1 | $6.4M | 82k | 78.01 | |
| Hologic (HOLX) | 1.1 | $6.2M | 180k | 34.60 | |
| Exelixis (EXEL) | 1.1 | $6.2M | 800k | 7.81 | |
| AmerisourceBergen (COR) | 1.1 | $6.2M | 78k | 79.32 | |
| Horizon Pharma | 1.1 | $6.1M | 370k | 16.47 | |
| Laboratory Corp. of America Holdings (LH) | 1.0 | $5.9M | 45k | 130.27 | |
| Alkermes (ALKS) | 1.0 | $5.9M | 136k | 43.22 | |
| Mednax (MD) | 1.0 | $5.8M | 80k | 72.42 | |
| Supernus Pharmaceuticals (SUPN) | 1.0 | $5.7M | 280k | 20.37 | |
| McKesson Corporation (MCK) | 1.0 | $5.6M | 30k | 186.67 | |
| Walgreen Boots Alliance (WBA) | 1.0 | $5.4M | 65k | 83.28 | |
| Humana (HUM) | 1.0 | $5.4M | 30k | 179.87 | |
| Endologix | 1.0 | $5.4M | 435k | 12.46 | |
| Lion Biotechnologies | 0.9 | $5.3M | 650k | 8.10 | |
| Anthem (ELV) | 0.9 | $5.3M | 40k | 131.35 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 0.9 | $5.2M | 60k | 86.02 | |
| Medivation | 0.9 | $4.8M | 80k | 60.30 | |
| Cerner Corporation | 0.8 | $4.7M | 81k | 58.60 | |
| Ariad Pharmaceuticals | 0.8 | $4.6M | 625k | 7.39 | |
| Intra Cellular Therapies (ITCI) | 0.8 | $4.5M | 115k | 38.82 | |
| Omnicell (OMCL) | 0.8 | $4.4M | 129k | 34.23 | |
| Zeltiq Aesthetics | 0.8 | $4.4M | 160k | 27.33 | |
| Dex (DXCM) | 0.8 | $4.4M | 55k | 79.33 | |
| Abbvie (ABBV) | 0.8 | $4.3M | 70k | 61.91 | |
| Cooper Companies | 0.8 | $4.3M | 25k | 171.56 | |
| Xencor (XNCR) | 0.8 | $4.3M | 225k | 18.99 | |
| Valeant Pharmaceuticals Int | 0.8 | $4.2M | 210k | 20.14 | |
| Nevro (NVRO) | 0.7 | $4.0M | 54k | 73.76 | |
| Macrogenics (MGNX) | 0.7 | $3.8M | 140k | 26.99 | |
| Radius Health | 0.7 | $3.7M | 100k | 36.75 | |
| Kite Pharma | 0.6 | $3.5M | 70k | 50.00 | |
| Livanova Plc Ord (LIVN) | 0.6 | $3.5M | 70k | 50.23 | |
| Abbott Laboratories (ABT) | 0.6 | $3.3M | 84k | 39.31 | |
| NxStage Medical | 0.6 | $3.2M | 145k | 21.68 | |
| Keryx Biopharmaceuticals | 0.5 | $3.0M | 450k | 6.62 | |
| Revance Therapeutics (RVNC) | 0.5 | $3.0M | 220k | 13.60 | |
| Cempra | 0.5 | $2.8M | 171k | 16.49 | |
| Becton, Dickinson and (BDX) | 0.5 | $2.5M | 15k | 169.60 | |
| Insulet Corporation (PODD) | 0.4 | $2.5M | 82k | 30.24 | |
| Portola Pharmaceuticals | 0.4 | $2.5M | 105k | 23.60 | |
| Neuroderm Ltd F | 0.4 | $2.3M | 145k | 16.25 | |
| Dynavax Technologies (DVAX) | 0.4 | $2.2M | 150k | 14.58 | |
| Coherus Biosciences (CHRS) | 0.4 | $2.2M | 131k | 16.89 | |
| Halozyme Therapeutics (HALO) | 0.4 | $2.2M | 250k | 8.63 | |
| Chimerix (CMRX) | 0.4 | $2.2M | 550k | 3.93 | |
| Community Health Systems (CYH) | 0.4 | $2.1M | 175k | 12.05 | |
| Achillion Pharmaceuticals | 0.4 | $2.1M | 266k | 7.80 | |
| Adamas Pharmaceuticals | 0.3 | $2.0M | 130k | 15.14 | |
| Rigel Pharmaceuticals (RIGL) | 0.3 | $1.9M | 850k | 2.23 | |
| Fibrogen (FGEN) | 0.3 | $1.9M | 114k | 16.41 | |
| Neurocrine Biosciences (NBIX) | 0.3 | $1.8M | 40k | 45.45 | |
| Perrigo Company (PRGO) | 0.3 | $1.8M | 20k | 90.65 | |
| ACADIA Pharmaceuticals (ACAD) | 0.3 | $1.6M | 50k | 32.46 | |
| Tandem Diabetes Care | 0.3 | $1.6M | 209k | 7.54 | |
| Esperion Therapeutics (ESPR) | 0.2 | $1.4M | 140k | 9.88 | |
| Array BioPharma | 0.2 | $1.3M | 370k | 3.56 | |
| Tetraphase Pharmaceuticals | 0.2 | $1.3M | 300k | 4.30 | |
| Catabasis Pharmaceuticals | 0.2 | $1.3M | 345k | 3.70 | |
| Regulus Therapeutics | 0.2 | $1.0M | 350k | 2.89 | |
| Anthera Pharmaceutcls | 0.2 | $927k | 300k | 3.09 | |
| Quorum Health | 0.1 | $602k | 56k | 10.70 | |
| Orexigen Therapeutics | 0.1 | $516k | 1.2M | 0.43 | |
| Ultragenyx Pharmaceutical (RARE) | 0.1 | $489k | 10k | 48.90 | |
| Adverum Biotechnologies | 0.1 | $487k | 154k | 3.16 | |
| Concert Pharmaceuticals I equity | 0.1 | $338k | 30k | 11.23 | |
| Mirati Therapeutics | 0.1 | $273k | 50k | 5.46 | |
| Ocular Therapeutix (OCUL) | 0.0 | $198k | 40k | 4.95 | |
| Glaukos (GKOS) | 0.0 | $149k | 5.1k | 29.22 | |
| Threshold Pharmaceuticals | 0.0 | $129k | 202k | 0.64 |
